Vitamin D, an Essential Nutrient with Versatile Functions in Nearly all Organs

Elisabeth Stöcklin and Manfred Eggersdorfer

DSM Nutritional Products Ltd., Kaiseraugst, Switzerland

Abstract: For decades, vitamin D has been known to be essential in the development, function, and maintenance of healthy bones through the regulation of calcium homeostasis throughout life. Sufficient vitamin D prevents the occurrence of rickets in children and osteomalacia in adults. The adequate nutritional intake of vitamin D and calcium are the basis for the prevention and management of osteoporosis, a disease producing brittle bones that are prone to fractures. Vitamin D has been implicated in the regulation of neuromuscular function and in reducing the risk of falls, a major cause of bone fractures. Thus vitamin D may be a central component of musculoskeletal health through its beneficial effects on muscle function and bone stability. The action of vitamin D by the active metabolite 1,25-dihydroxyvitamin D $[1,25(OH)_2D]$, however, is not limited to its endocrine function in bone metabolism. The active metabolite behaves as a hormone and binds to the vitamin D receptor (VDR) present in nearly all tissues of the human body. In addition, the 1-alpha-hydroxylase enzyme is present not only in the kidney but also in many other organs. Both vitamin and enzyme exert their biological effects via paracrine/autocrine actions related to cardiovascular disease, diabetes, cancer, and the immune system. Thus vitamin D may show favorable effects in many organs and play a significant role in the maintenance of general health.

Key words: vitamin D, vitamin D deficiency, recommendations, fractures, falls, health benefits

Vitamin D sources

Vitamin D is a unique nutrient because it can come from two sources. It is part of the diet, but it can also be synthesized in the skin through the action of sunlight. Both sources complement each other to meet physiological requirements. In the absence of ultraviolet-B (UVB) sunlight exposure, dietary vitamin D becomes an essential nutrient. Vitamin D from the diet is provided as cholecalciferol (D3, from animal sources) or as ergocalciferol (D2, from plant sources). However,

few food sources are rich in natural vitamin D, like fatty fish, herring, salmon, or eel. But the body has evolved an efficient method of synthesizing vitamin D in the skin following exposure to sunlight (UVB radiation) providing the major source of vitamin D. The endogenous dermal production of vitamin D, however, is limited by several factors. Vitamin D synthesis is reduced at latitudes greater than 37°, especially in the winter. It is also dependent on the time of day, and is restricted by air pollution and weather conditions. Dark-skinned individuals and people using

sunscreen synthesize less vitamin D on sunlight exposure [1, 2]. Furthermore, elderly and institutionalized people with limited sunlight exposure are vulnerable and synthesize inadequate vitamin D levels. Skin-covering clothes, indoor lifestyles, and even obesity can become further limiting factors [1, 3, 4]. It becomes crucial, then, to find a reasonable balance of sun exposure, i.e. a dose that provides the daily requirements for optimal human health, but avoids the excessive sun exposure associated with skin cancer. Since such optimal conditions cannot always be met, vitamin D supplementation or food fortification becomes an important health issue.

Vitamin D metabolism

Vitamin D is an essential nutrient and as such is biologically inert. After absorption and distribution via the circulation, vitamin D is converted in the liver to 25-hydroxyvitamin D [25(OH)D], the major circulating vitamin D metabolite. This 25(OH)D metabolite is usually measured in serum and reflects the vitamin D status. The conversion of this compound into the classic endocrine functional metabolite occurs in the kidney. 25(OH)D is metabolized by the enzyme 1-alpha-hydroxylase (CYP27B1) to the active form 1,25-dihydroxyvitamin D [1,25(OH)$_2$D], which is thought to be responsible for most of the biological functions [5]. 1,25(OH)$_2$D regulates serum calcium and phosphorus homeostasis by intestinal calcium and phosphate absorption and thus exerts a favorable effect on bone mineralization. The activation step of 1,25(OH)$_2$D at the kidney is tightly regulated by parathyroid hormone (PTH) in response to serum calcium and phosphorus level, and by the fibroblast growth factor-23 (FGF-23). Active vitamin D [1,25(OH)$_2$D] functions as a ligand for the vitamin D receptor, VDR. This receptor belongs to the nuclear receptor family and acts as a transcription factor upon ligand activation. The VDR interacts with the retinoid X receptor (RXR) to form a heterodimer that binds to the vitamin D-responsive element to initiate biological responses [6, 7]. The VDR is expressed in at least 38 types of tissue [8]. Beside the endocrine function, the active metabolite 1,25(OH)$_2$D also acts via a paracrine/autocrine function on the VDR. In addition to the kidney, many tissues in the body possess the 1-alpha-hydroxylation enzyme (CYP27B1) and thus convert 25(OH)D to the active 1,25(OH)$_2$D, dependent upon local needs. This non-renal hydroxylation step is not under negative feedback control, but is regulated locally by cytokines and the substrate, the intermediate metabolite 25(OH)D [9–12]. An adequate vitamin D status is important for optimal function of many organs. The VDR functions either as a nuclear transcription factor activating specific genes, or by a non-genomic action, modulating rapid signal transduction pathways in plasma membranes [6, 13, 14]. Both affect various recently identified biological actions of 1,25(OH)$_2$D such as regulation of cell differentiation and proliferation, apoptosis, hormone secretion, and immune modulations. This could explain the molecular basis by which vitamin D benefits various tissues and organs; e.g., the muscles, the cardiovascular and immune systems, the brain, and others [8]. About 3 % of the human genome is regulated directly or indirectly by vitamin D metabolites [3, 15].

Assessment of vitamin D status and optimal serum levels

Circulating 25(OH)D is a sensitive marker to assess vitamin D status. Its levels reflect both dietary vitamin D intake and the endogenous dermal vitamin D production. There is a general agreement that serum 25(OH)D is the best indicator of vitamin D status [4]. It is widely accepted that 25(OH)D below 25 nmol/L is the lower threshold that defines deficiency [16]. However, no consensus has been reached on the definition of a required or adequate serum 25(OH)D level: Should it be higher than 50 nmol/L or even exceed 75 nmol/L? The Institute of Medicine (IOM) has recently stated that a serum level of 25(OH)D at or above 50 nmol/L is adequate for the general population for bone health. This opinion has been questioned by vitamin D experts [17–19]. They favor a 25(OH)D level of more than 75 nmol/L. It has been reported that parathyroid hormone (PTH) levels [20] and calcium absorption [21] are not optimal unless serum 25(OH)D levels reach 75–80 nmol/L [9]. In addition, clinical trials and epidemiologic studies suggest various health benefits of 25(OH)D levels above 75 nmol/L [18, 19, 22–25]. This has been summarized in a review on the risk-benefit assessment of vitamin D supplementation [26]. Data suggest that a mean serum 25(OH)D level of 75–110 nmol/L is positively associated with health benefits for various endpoints, including fall and fracture prevention. This observation has also been supported by epidemiologic data on cardiovascular health, colorectal cancer, incident hypertension, and general mortality [3, 27–30]. Vitamin D experts favor serum 25(OH)D levels above 75 nmol/L to optimize

health [18, 31 – 34]. However, further clinical trials are warranted to evaluate the beneficial effects of greater doses of vitamin D (above 1000 IU) on skeletal and non-skeletal health outcomes and on the 25(OH)D threshold level.

Vitamin D deficiency is a global concern

Vitamin D deficiency is widespread around the globe even in countries with long hours of sunshine. It is a re-emerging health problem. The risk for vitamin D deficiency increases with age, especially in institutionalized and geriatric people [35]. Furthermore vitamin D deficiency has become an epidemic in children, and rickets has again become a global health issue [1,36]. Non-Western immigrants, particularly from African Caribbean, Middle East, and South Asian origins immigrated to Northern European Countries show a high risk of vitamin D deficiency [1, 35, 37 – 39]. A recent review of the global vitamin D status found that serum 25(OH)D levels below 75 nmol/L are prevalent in every region of the world investigated [40]. Levels below 25 nmol/L, reflecting severe vitamin D deficiency, are most common in South Asia and the Middle East [38, 41]. In European countries, the prevalence of severe vitamin D deficiency, below 25 nmol/L, is between 2 – 30 % in adults, and is increased in the older population and in homebound and institutionalized people, to more than 80 % [35, 42]. Clinical symptoms such as bone disease and muscle weakness may occur when serum 25(OH)D levels fall below 25 nmol/L. In the USA and other developed countries, 25(OH)D levels have dropped significantly in the last decade [2]. The decline in vitamin D status appears to be contributed to by several environmental factors such as general increase in sun avoidance and in sun protection, changes in lifestyle, and an increase in obesity [2, 43]. Moreover, vitamin D deficiency has been associated with adverse health effects in many countries [44].

Dietary Recommendations for vitamin D

National recommendations for dietary vitamin D are not harmonized across the European Union and vary from 200 to 400 IU [16, 45]. Even a recommended intake of 400 IU has been shown to be insufficient to prevent falls and bone fracture [46]. Higher recommendations for dietary vitamin D intake are increasingly being suggested in government documents, position statements, and clinical practice guidelines for bone health. In 2008, the U.S. Food and Drug Administration updated the health claim for the prevention of osteoporosis by adding vitamin D to the consumption of calcium [47]. In 2008 the American Academy of Pediatrics (AAP) also reacted and issued an update of their guidelines for vitamin D intake and rickets prevention. They doubled the recommended dose of vitamin D for children to 400 IU per day, beginning in the first few days of life and continuing throughout adolescence [48]. In 2010, the Institute of Medicine (IOM) released the revised Dietary Reference Intakes (DRIs) for calcium and vitamin D and tripled the recommendations for vitamin D intakes to 600 IU per day for children and all adults up to age 69 years. They also increased it to 800 IU per day for those 70 years and older. The IOM has set the recommendation for the general population based primarily on the need for bone health and concluded that a serum 25(OH)D above 50 nmol/L will cover the requirements of 97.5 % of the population to maintain healthy bones [4]. The IOM stated that there was insufficient evidence to make recommendations for non-skeletal benefits. In January 2012 the German, Austrian, and Swiss Nutrition Societies raised the recommended vitamin D intake to 800 IU per day, in the case of absent UVB exposure, for all age groups starting from one year of age [49]. Furthermore, key opinion leaders are increasingly recommending higher daily intakes for vitamin D, between 800 – 1000 IU or even higher for people at risk or older adults. The recent statement by the International Osteoporosis Foundation (IOF) [50] and the guidelines by the U.S. Endocrine Society [51, 52] suggest that higher vitamin D doses would be needed to achieve the desirable 25(OH)D serum level of 75 nmol/L, for people at risk or for older individuals. In contrast to the IOM, the IOF and the U.S. Endocrine Society recommend vitamin D for the prevention of falls for the elderly as do the American Geriatric Society and British Geriatric Society in their 2010 Clinical Practical Guidelines for fall prevention for the elderly [53].

However, the 25(OH)D response to vitamin D supplementation is highly variable and thus it becomes difficult to select the "optimal" vitamin D dose needed for a beneficial effect. No consensus exists currently about optimal 25(OH)D threshold levels. Several large-scale randomized controlled trials on higher vitamin D doses are in progress, which may clarify the scientific evidence for vitamin D [54].

Vitamin D has a dual role in preventing fractures

Vitamin D is essential to maintaining bone health, but is also thought to be important for muscle function and balance. Thus vitamin D may play a dual role in preventing fractures: it directly increases bone density, and it improves muscle strength [55] and balance [56]. Both effects reduce the risk of falling [57, 58]. Results from NHANES III which included younger and older individuals from different ethnic groups, reported a positive association between higher 25(OH)D serum levels and higher bone mineral density [59]. There is biological plausibility that vitamin D has a direct favorable effects on muscle function [9, 15]. Several observational studies have pointed to a beneficial association between increased 25(OH)D serum levels and muscle strength or improved lower extremity function [60–62]. Clinical intervention studies have reported that vitamin D reduces the risk of falls and fractures only at higher vitamin D intakes (800–1000 IU) or at higher achieved serum 25(OH)D levels. These randomized controlled trials (RCTs) have been summarized in systematic reviews reporting a significant reduction in the risk of fall prevention [58, 61, 63]. However, there is still conflicting interpretation of the clinical evidence on vitamin D and falls. The IOF [50] and the U.S. Endocrine Society [51, 52] recommend vitamin D for the prevention of falls for the elderly in contrast to the IOM, stating that there is insufficient evidence to make recommendations for fall prevention [4]. The main discrepancy was in the interpretation of data, inclusion of RCTs, and the dose and regimen [63–65].

A 25(OH)D level between 50 and 75 nmol/L is positively associated with an improvement in bone health, but for optimal functionality data suggests a 25(OH)D threshold of 75 nmol/L for fracture prevention among the elderly [66]. The higher threshold has been addressed in a risk-benefit analysis and is further supported by meta-analysis [46, 58, 67].

On the basis of these data the European Food Safety Authorities (EFSA) have recently issued a positive opinion on health claim Article 14 on the use of vitamin D to reduce the risk of falls and fractures in the elderly [68].

Vitamin D deficiency has multiple consequences beyond bone health

Vitamin D exerts biological functions beyond calcium homeostasis and bone metabolism through paracrine/autocrine actions, and through the presence of the VDR in virtually all cells of the body. 1,25(OH)$_2$D can be made locally to initiate biological responses to affect many organs and organ systems.

Available promising observational studies supported by plausible biological mechanisms and prospective studies suggest largely, but not consistently, a significant role for vitamin D in multiple health outcomes. Many of these beneficial associations are quite well established. Causation however needs still to be proven by large-scale, long-term randomized clinical trials [14, 69].

Evidence from large population studies suggests a strong inverse correlation mainly between vitamin D deficiency and higher risk of cardiovascular outcomes [3] such as increased risk of myocardial infarction [70], stroke, and heart failure [71–73]. The association between vitamin D deficiency and hypertension has been reported in epidemiologic studies supported by small intervention studies and physiological explanations [74, 75]. All these observations favor the hypothesis that vitamin D may play an important role in the pathogenesis of cardiovascular diseases, causation however, has still to be proven. Vitamin D has also been recognized to strengthen the immune system affecting both the innate and adaptive immune response [76–78]. Vitamin D may prevent or delay auto-immune diseases, such as diabetes mellitus Type 1 [79–80] and multiple sclerosis [81, 82]. In population studies the rate of auto-immune disease and cancer is increased at higher latitudes, and is significantly more prevalent at northern latitudes of Europe, the U.S., and the southern part of Australia, correlating well with the increased prevalence of vitamin D deficiency at higher latitudes [3, 38, 83]. Additionally, vitamin D influences adequate immune response and has effects on the defense against respiratory tract infections [84, 85] and tuberculosis [86]. Experimental data suggest that vitamin D inhibits bacterial growth [87] and decreases pro-inflammatory cytokines [88]. Moreover, in the pre-antibiotic area very high doses of vitamin D were used to treat tuberculosis [89]. Epidemiologic data have indicated an association between vitamin D deficiency and increased rate of mortality [28, 32, 90, 91], supported by a meta-analysis of 9 randomized controlled trials [27]. However, the findings from observational studies are not consistent [28, 92]. Newer data from epidemiologic studies suggest that vitamin D deficiency may have consequences on various chronic diseases, classified as non-communicable diseases (NCDs), especially in the elderly [44, 93]. These chronic diseases are the leading cause of disability and morbidity in seniors.

Vitamin D Safety

The main adverse outcome of excessive vitamin D intake is associated with hypercalcemia and hypercalciuria and related clinical symptoms. Renal stones, nephrocalcinosis, and renal function impairment can occur. Vitamin D toxicity is rare. Only a few cases of 25(OH)D levels above 500 nmol/L have been described, affecting individuals after accidental intake of high doses of vitamin D [94, 95]. To reach such high serum levels of 25(OH)D, healthy adults must consume at least 30,000 to 50,000 IU of vitamin D per day for an extended period of time [94, 96]. It must be noted that the IOM considers a circulating 25(OH)D above 125 nmol/L as potentially harmful [4]. A review on a risk assessment of vitamin D that re-analyzed controlled clinical trials concluded that a daily intake of 10,000 IU vitamin D can be considered as safe [97]. In a review of a risk-benefit assessment on vitamin D supplementation, a safe upper intake level of 10,000 IU of vitamin D per day has been suggested [26], which is further supported by a recent evaluation on the safety of oral vitamin D, concluding that long-term daily intakes of up to 10,000 IU of vitamin D are safe [96]. Additionally, no adverse effects were noted by the IOM at intakes up to 10,000 IU/day [4]. This is far more than the current vitamin D recommendations for adults, which range globally between 400 to 800 IU vitamin D per day. Furthermore in 2010, the Institute of Medicine (IOM) has set the upper safe limit (UL) at 4000 IU per day. This is double the amount previously recommended. In 2012 the European Food Safety Authority (EFSA) released the updated Tolerable Intake Levels (ULs) of vitamin D as 4000 IU for adults and for ages 11–17 year; a UL of 2000 IU has been proposed for children aged 1–10 years [98].

Conclusions

Several epidemiological studies have reported an association between vitamin D deficiency and increased risk of heart disease, hypertension, autoimmunity disorders, cancer, and even mortality. However, a causal relationship still needs to be proven. Findings from intervention studies demonstrate that vitamin D is important and support its beneficial role in reducing the risk of fractures and falls, at levels of vitamin D intake between 700 and 1000 IU. Several large-scale randomized controlled trials on higher vitamin D doses are ongoing, which may clarify the scientific evidence for vitamin D on health outcomes. Consensus

on the optimal 25(OH)D threshold level is, however, not yet reached. The IOM recommends a 25(OH)D serum level above 50 nmol/L as sufficient, whereas key opinion leaders and guidelines by the IOF and the U.S. Endocrine Society suggest a threshold of 75 nmol/L as desirable for fracture prevention and optimal health. To achieve sufficient levels requires a significant increase of the current recommended daily intakes for adults in all countries to ensure adequate vitamin D nutrition. To address this need, the IOM as well as the European Nutrition Societies have issued updates of their guidelines and increased the recommended daily dose for all age groups: i. e. between 600 IU and 800 IU of vitamin D for adults. Even with a balanced diet, 800 IU of vitamin D per day is difficult to achieve in the absence of sunlight, which would mean consuming 2 portions of oily fish or 40 eggs per day. Vitamin D deficiency is a major public health burden in many parts of the world. There is an urgent need to take action and improve the vitamin D status of the public. This situation points to a need for supplementation or fortification of foods for maintaining a sufficient vitamin D status for the general population.

References

1. Prentice, A. (2008) Vitamin D deficiency: a global perspective. Nutr. Rev. 66, S153–1642.

2. Ginde, A.A., Liu, M.C., Camargo and C.A., Jr. (2009) Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch. Intern. Med. 169, 626–632.

3. Holick, M.F. (2007) Vitamin D deficiency. N. Engl. J. Med. 357, 266–281.

4. IOM (2011) Dietary Reference Intakes for Calcium and Vitamin D. The National Academies Press, Washington, D.C.

5. DeLuca, H.F., Sicinski, R.R., Tanaka, Y., Stern, P.H. and Smith, C.M. (1988) Biological activity of 1,25-dihydroxyvitamin D2 and 24-epi-1,25-dihydroxyvitamin D2. Am. J. Physiol. 254, E402–406.

6. Haussler, M.R., Jurutka, P.W., Mizwicki, M. and Norman, A.W. (2011) Vitamin D receptor (VDR)-mediated actions of 1-alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 25, 543–559.

7. Haussler, M.R., Whitfield, G.K., Kaneko, I. Haussler, C.A., Hsieh, D., Hsieh, J.C. and Jurutka, P.W. (2013)

Molecular mechanisms of vitamin D action. Calcif. Tissue Int. 92, 77–98.

8. Norman, A.W. and Bouillon, R. (2010) Vitamin D nutritional policy needs a vision for the future. Exp. Biol. Med. (Maywood) 235, 1034–1045.

9. Adams, J.S. and Hewison, M. (2010) Update in vitamin D. J. Clin. Endocrinol. Metab. 95, 471–478.

10. Holick, M.F. (2006) High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 81, 353–373.

11. Liu, P.T., Stenger, S., Li, H. et al. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770–1773.

12. Schauber, J., Dorschner, R.A., Coda, A.B. et al. (2007) Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J. Clin. Invest. 117, 803–811.

13. Norman, A.W. (2006) Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147, 5542–5548.

14. Rosen, C.J., Adams, J.S., Bikle, D.D., Black, D.M., Demay, M.B., Manson, J.E., Murad, M.H. and Kovacs, C.S. (2012) The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr. Rev. 33, 456–492.

15. Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer, H.F., Lieben, L., Mathieu, C. and Demay, M. (2008) Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr. Rev. 29, 726–776.

16. Lanham-New S.A., Buttriss, J.L., Miles, L.M. et al. (2011) Proceedings of the Rank Forum on Vitamin D. Br. J. Nutr. 105, 144–156.

17. Heaney, R.P. and Holick, M.F. (2011) Why the IOM recommendations for vitamin D are deficient. J. Bone Miner. Res. 26, 455–457.

18. Vieth, R. (2011) Why the minimum desirable serum 25-hydroxyvitamin D level should be 75 nmol/L (30 ng/ml). Best Pract. Res. Clin. Endocrinol. Metab. 25, 681–691.

19. Hollis, B.W. (2011) Short-term and long-term consequences and concerns regarding valid assessment of vitamin D deficiency: comparison of recent food supplementation and clinical guidance reports. Curr. Opin. Clin. Nutr. Metab. Care 14, 598–604.

20. Thomas, M.K., Lloyd-Jones, D.M., Thadhani, R.I., Shaw, A.C., Deraska, D.J., Kitch, B.T., Vamvakas, E.C., Dick, I.M., Prince, R.L. and Finkelstein, J.S. (1998) Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 338, 777–783.

21. Heaney, R.P. (2005) The Vitamin D requirement in health and disease. J. Steroid Biochem. Mol. Biol. 97, 13–19.

22. Heaney, R.P. (2013) What Is Vitamin D Insufficiency? And Does It Matter? Calcif. Tissue Int. 92(2): 177–83.

23. Priemel, M., von Domarus, C., Klatte, T.O. et al. (2010) Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res. 25, 305–312.

24. Stockton, K.A., Mengersen, K., Paratz, J.D., Kandiah, D. and Bennell, K.L. (2011) Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos. Int. 22, 859–871.

25. Trivedi, D.P., Doll, R. and Khaw, K.T. (2003) Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 326, 469.

26. Bischoff-Ferrari, H.A., Shao, A., Dawson-Hughes, B., Hathcock, J., Giovannucci, E. and Willett, W.C. (2010) Benefit-risk assessment of vitamin D supplementation. Osteoporos. Int. 21, 1121–1132.

27. Autier, P. and Gandini, S. (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 167, 1730–1737.

28. Melamed, M.L., Michos, E.D., Post, W. and Astor, B. (2008) 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 168, 1629–1637.

29. Pilz, S., Iodice, S., Zittermann, A., Grant, W.B. and Gandini, S. (2011) Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am. J. Kidney Dis. 58, 374–382.

30. Wang, T.J., Pencina, M.J., Booth, S.L., Jacques, P.F., Ingelsson, E., Lanier, K., Benjamin, E.J., D'Agostino, R.B., Wolf, M. and Vasan, R.S. (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117, 503–511.

31. Dawson-Hughes, B., Heaney, R.P., Holick, M.F., Lips, P., Meunier, P.J. and Vieth, R. (2005) Estimates of optimal vitamin D status. Osteoporos. Int. 16, 713–716.

32. Zittermann, A., Iodice, S., Pilz, S., Grant, W.B., Bagnardi, V. and Gandini, S. (2012) Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am. J. Clin. Nutr. 95, 91–100.

33. Grant, W.B. (2011) An estimate of the global reduction in mortality rates through doubling vitamin D levels. Eur. J. Clin. Nutr. 65, 1016–1026.

34. Bischoff-Ferrari, H.A., Giovannucci, E., Willett, W.C., Dietrich, T. and Dawson-Hughes, B. (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18–28.

35. van Schoor, N.M. and Lips, P. (2011) Worldwide vitamin D status. Best Pract. Res. Clin. Endocrinol. Metab. 25, 671–680.

36. Holick, M.F. (2006) Resurrection of vitamin D deficiency and rickets. J. Clin. Invest. 116, 2062–2072.

37. Hypponen, E. and Power, C. (2007) Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am. J. Clin. Nutr. 85, 860–868.

38. Lips, P. (2010) Worldwide status of vitamin D nutrition. J. Steroid Biochem. Mol. Biol. 121, 297–300.

39. van der Meer, I.M., Middelkoop, B.J., Boeke, A.J. and Lips, P. (2011) Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and sub-Sahara African populations in Europe and their countries of origin: an overview. Osteoporos. Int. 22, 1009–1021.

40. Wahl, D.A., Cooper, C., Ebeling, P.R. et al. (2012) A global representation of vitamin D status in healthy populations. Arch. Osteoporos. 7, 155–172.

41. Mithal, A., Wahl, D.A., Bonjour, J.P., Burckhardt, P., Dawson-Hughes, B., Eisman, J.A., El-Hajj Fuleihan, G., Josse, R.G., Lips, P. and Morales-Torres, J. (2009) Global vitamin D status and determinants of hypovitaminosis D. Osteoporos. Int. 20, 1807–1820

42. Lips, P. (2007) Vitamin D status and nutrition in Europe and Asia. J. Steroid Biochem. Mol. Biol. 103, 620–625.

43. Looker, A.C., Pfeiffer, C.M., Lacher, D.A., Schleicher, R.L., Picciano, M.F. and Yetley, E.A. (2008) Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am. J. Clin. Nutr. 88, 1519–1527.

44. Holick, M.F. and Chen, T.C. (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87, 1080S–1086S.

45. Doets, E.L., de Wit, L.S., Dhonukshe-Rutten, R.A. et al. (2008) Current micronutrient recommendations in Europe: towards understanding their differences and similarities. Eur. J. Nutr. 47 Suppl 1, 17–40.

46. Bischoff-Ferrari, H.A., Willett, W.C., Wong, J.B., Stuck, A.E., Staehelin, H.B., Orav, E.J., Thoma, A., Kiel, D.P. and Henschkowski, J. (2009) Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 169, 551–561.

47. FDA (2008) FDA Updates Health Claim for Calcium and Osteoporosis. https://wwwfederalregistergov/articles/2008/09/29/E8–22730/food-labeling-health-claims-calcium-and-osteoporosis-and-calcium-vitamin-d-and-osteoporosis

48. Wagner, C.L. and Greer, F.R. (2008) Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 122, 1142–1152.

49. New Recommendations for vitamin D by the Nutrition Society (D A, CH) (2012) Die Referenzwerte für die Nährstoffzufuhr Vitamin D (D-A-CH Referenzwerte der DGE, ÖGE, SGE/SVE). http://wwwdgede/modulesphp?name=Content&pa=showpage&pid=4&page=12

50. Dawson-Hughes, B., Mithal, A., Bonjour, J.P., Boonen, S., Burckhardt, P., Fuleihan, G.E., Josse, R.G., Lips, P., Morales-Torres, J. and Yoshimura, N. (2010) IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 21, 1151–1154.

51. Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., Murad, M.H. and Weaver, C.M. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 1911–1930.

52. Holick, M.F. (2012) Evidence-based D-bate on health benefits of vitamin D revisited. Dermatoendocrinol. 4, 183–190.

53. Panel on Prevention of Falls in Older Persons AGS/BGS (2010) Summary of the Updated American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons. Journal of the American Geriatrics Society 59, 148–157.

54. Kupferschmidt, K. (2012) Uncertain verdict as vitamin D goes on trial. Science 337, 1476–1478.

55. Bischoff-Ferrari, H.A., Dietrich, T., Orav, E.J., Hu, F.B., Zhang, Y., Karlson, E.W. and Dawson-Hughes, B. (2004) Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y. Am. J. Clin. Nutr. 80, 752–758.

56. Pfeifer, M., Begerow, B., Minne, H.W., Abrams, C., Nachtigall, D. and Hansen, C. (2000) Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J. Bone Miner. Res. 15, 1113–1118.

57. Pfeifer, M., Begerow, B., Minne, H.W., Suppan, K., Fahrleitner-Pammer, A. and Dobnig, H. (2009) Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos. Int. 20, 315–322.

58. Bischoff-Ferrari, H.A., Dawson-Hughes, B., Staehelin, H.B., Orav, J.E., Stuck, A.E., Theiler, R., Wong, J.B., Egli, A., Kiel, D.P. and Henschkowski, J. (2009) Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339, b3692.

59. Bischoff-Ferrari, H.A., Dietrich, T., Orav, E.J. and Dawson-Hughes, B. (2004) Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am. J. Med. 116, 634–639.

60. Wicherts, I.S., van Schoor, N.M., Boeke, A.J., Visser, M., Deeg, D.J., Smit, J., Knol, D.L. and Lips, P. (2007) Vitamin D status predicts physical performance and its decline in older persons. J. Clin. Endocrinol. Metab. 92, 2058–2065.

61. Bischoff-Ferrari, H.A., Dawson-Hughes, B., Willett, W.C., Staehelin, H.B., Bazemore, M.G., Zee, R.Y. and Wong, J.B. (2004) Effect of Vitamin D on falls: a meta-analysis. JAMA 291, 1999–2006.

62. Snijder, M.B., van Schoor, N.M., Pluijm, S.M., van Dam, R.M., Visser, M. and Lips, P. (2006) Vitamin D status in relation to one-year risk of recurrent falling in older men and women. J. Clin. Endocrinol. Metab. 91, 2980–2985.

63. Murad, M.H., Elamin, K.B., Abu Elnour, N.O. et al. (2011) Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 2997–3006.

64. Brouwer-Brolsma, E.M., Bischoff-Ferrari, H.A., Bouillon, R. et al. (2013) Vitamin D: do we get enough? A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe. Osteoporos. Int. 24, 1567–1577.

65. Heaney, R.P. (2012) Vitamin D–baseline status and effective dose. N. Engl. J. Med. 367, 77–78.

66. Dawson-Hughes, B. (2013) What is the optimal dietary intake of vitamin D for reducing fracture risk? Calcif. Tissue Int. 92, 184–190.

67. Bischoff-Ferrari, H.A., Willett, W.C., Orav, E.J. et al. (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med. 367, 40–49.

68. EFSA (2011) Scientific Opinion on the substantiation of a health claim related to vitamin D and risk of falling pursuant to Article 14 of Regulation (EC) No 1924/2006 http://wwwefsaeuropaeu/en/efsajournal/pub/2382htm

69. Wacker, M. and Holick, M.F. (2013) Vitamin D – effects on skeletal and extraskeletal health and the need for supplementation. Nutrients 5, 111–148.

70. Giovannucci, E., Liu, Y., Hollis, B.W. and Rimm, E.B. (2008) 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 168, 1174–1180.

71. Zittermann, A., Gummert, J.F. and Borgermann, J. (2011) The role of vitamin D in dyslipidemia and cardiovascular disease. Curr. Pharm. Des. 17, 933–942.

72. Judd, S.E. and Tangpricha, V. (2009) Vitamin D deficiency and risk for cardiovascular disease. Am. J. Med. Sci. 338, 40–44.

73. Anderson, J.L., May, H.T., Horne, B.D., Bair, T.L., Hall, N.L., Carlquist, J.F., Lappe, D.L. and Muhlestein, J.B. (2010) Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am. J. Cardiol. 106, 963–968.

74. Forman, J.P., Giovannucci, E., Holmes, M.D., Bischoff-Ferrari, H.A., Tworoger, S.S., Willett, W.C. and Curhan, G.C. (2007) Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 49, 1063–1069.

75. Pilz, S., Tomaschitz, A., Ritz, E. and Pieber, T.R. (2009) Vitamin D status and arterial hypertension: a systematic review. Nat. Rev. Cardiol. 6, 621–630.

76. Holick, M.F. (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80, 1678S–1688S.

77. Baeke, F., Takiishi, T., Korf, H., Gysemans, C. and Mathieu, C. (2010) Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 10, 482–496.

78. Cannell, J.J., Vieth, R., Umhau, J.C., Holick, M.F., Grant, W.B., Madronich, S., Garland, C.F. and Giovannucci, E. (2006) Epidemic influenza and vitamin D. Epidemiol. Infect. 134, 1129–1140.

79. Hypponen, E., Laara, E., Reunanen, A., Jarvelin, M.R. and Virtanen, S.M. (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358, 1500–1503.

80. Zipitis, C.S. and Akobeng, A.K. (2008) Vitamin D supplementation in early childhood and risk of type

1 diabetes: a systematic review and meta-analysis. Arch. Dis. Child. 93, 512–517.

81. Smolders, J., Menheere, P., Thewissen, M., Peelen, E., Tervaert, J.W.C., Hupperts, R. and Damoiseaux, J. (2010) Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. Journal of Steroid Biochemistry and Molecular Biology 121, 243–246.

82. Munger, K.L., Levin, L.I., Hollis, B.W., Howard, N.S. and Ascherio, A. (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Journal of the American Medical Association 296, 2832–2838.

83. Mohr, S.B., Garland, C.F., Gorham, E.D. and Garland, F.C. (2008) The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 51, 1391–1398.

84. Urashima, M., Segawa, T., Okazaki, M., Kurihara, M., Wada, Y. and Ida, H. (2010) Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am. J. Clin. Nutr. 91, 1255–1260.

85. Laaksi, I., Ruohola, J.P., Mattila, V., Auvinen, A., Ylikomi, T. and Pihlajamaki, H. (2010) Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men. J. Infect. Dis. 202, 809–814.

86. Nnoaham, K.E. and Clarke, A. (2008) Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int. J. Epidemiol. 37, 113–119.

87. Liu, N., Kaplan, A.T., Low, J., Nguyen, L., Liu, G.Y., Equils, O. and Hewison, M. (2009) Vitamin D induces innate antibacterial responses in human trophoblasts via an intracrine pathway. Biol. Reprod. 80, 398–406.

88. Canning, M.O., Grotenhuis, K., de Wit, H., Ruwhof, C. and Drexhage, H.A. (2001) 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur. J. Endocrinol. 145, 351–357.

89. Martineau, A.R., Honecker, F.U., Wilkinson, R.J. and Griffiths, C.J. (2007) Vitamin D in the treatment of pulmonary tuberculosis. J. Steroid Biochem. Mol. Biol. 103, 793–798.

90. Dobnig, H., Pilz, S., Scharnagl, H., Renner, W., Seelhorst, U., Wellnitz, B., Kinkeldei, J., Boehm, B.O., Weihrauch, G. and Maerz, W. (2008) Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 168, 1340–1349.

91. Ginde, A.A., Scragg, R., Schwartz, R.S. and Camargo, C.A., Jr. (2009) Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. J. Am. Geriatr. Soc. 57, 1595–1603.

92. Michaelsson, K., Baron, J.A., Snellman, G., et al. (2010) Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am. J. Clin. Nutr. 92, 841–848.

93. Tuohimaa, P. (2009) Vitamin D and aging. J. Steroid Biochem. Mol. Biol. 114, 78–84.

94. Heaney, R.P. (2008) Vitamin D: criteria for safety and efficacy. Nutr. Rev. 66, S178–181.

95. Vieth, R. (2007) Vitamin D toxicity, policy, and science. J. Bone Miner. Res. 22 Suppl 2, V64–68.

96. Glade, M.J. (2012) A 21st century evaluation of the safety of oral vitamin D. Nutrition 28, 344–356.

97. Hathcock, J.N., Shao, A., Vieth, R. and Heaney, R. (2007) Risk assessment for vitamin D. Am. J. Clin. Nutr. 85, 6–18.

98. (2012) European Food Safety Authorities (EFSA) re-evaluated Tolerable Upper Intake Levels (ULs) http://www.efsa.europa.eu/en/efsajournal/pub/2813.htm

Dr. Elisabeth Stöcklin

DSM Nutritional Products Ltd.
Bldg 203/185
Wurmisweg 576
4303 Kaiseraugst
Switzerland
elisabeth.stoecklin@dsm.com